Evercore ISI Group Downgrades Sarepta Therapeutics to Neutral, Announces $139 Price Target
Portfolio Pulse from richadhand@benzinga.com
Evercore ISI Group analyst Gavin Clark-Gartner downgrades Sarepta Therapeutics (NASDAQ:SRPT) from Outperform to Neutral and announces a $139 price target.

June 23, 2023 | 12:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Sarepta Therapeutics downgraded to Neutral by Evercore ISI Group, with a $139 price target.
The downgrade from Outperform to Neutral by Evercore ISI Group analyst Gavin Clark-Gartner indicates a less optimistic outlook for Sarepta Therapeutics. This could lead to a short-term negative impact on the stock price as investors may adjust their positions based on the new rating and price target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100